Literature DB >> 20676802

Effects of PACAP on oxidative stress-induced cell death in rat kidney and human hepatocyte cells.

Gabriella Horvath1, Reka Brubel, Krisztina Kovacs, Dora Reglodi, Balazs Opper, Andrea Ferencz, Peter Szakaly, Eszter Laszlo, Lidia Hau, Peter Kiss, Andrea Tamas, Boglarka Racz.   

Abstract

Oxidative stress plays an important role in various renal and hepatic pathologies, and reduction of oxidative stress-induced processes is an important protective strategy in tissues of diverse origins against harmful stimuli. Pituitary adenylate cyclase activating polypeptide (PACAP) is a well-known cytotrophic and cytoprotective peptide. PACAP promotes cell survival in numerous cells and tissues exposed to various stimuli. Protective effects of PACAP have been shown in the kidney, but it is not known whether PACAP is protective against oxidative stress in renal cells. Little is known about the effects of PACAP in the liver. The aim of the present study was to investigate whether PACAP is protective against oxidative stress in primary rat kidney cell culture and whether PACAP has any effect on cell survival in human WRL-68 hepatocytes and HEP-G2 hepatocellular carcinoma cells subjected to oxidative stress. Cells were exposed to various concentrations of H(2)O(2) with or without PACAP co-treatment and cell viability was evaluated with the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide test (MTT). We found that oxidative stress induced a significant decrease in cell viability in both cell lines. PACAP could dose-dependently increase the percentage of living cells in kidney cells, but it failed to do so in hepatocytes. Given the survival-promoting effects of PACAP against oxidative stress in rat kidney, we conducted a further experiment to determine whether PACAP influences the markers of oxidative stress in vivo. We have proven earlier that PACAP was effective in kidney ischemia/reperfusion injury in vivo. In the present study, we determined the levels of the oxidative stress marker malondialdehyde and the activity of the scavenger molecules glutathione (GSH) and superoxide dismutase (SOD) following kidney ischemia/reperfusion in rats. We found that PACAP significantly increased the level of GSH and counteracted the marked reduction of SOD activity after ischemia/reperfusion in vivo. In summary, the present study showed that while PACAP was able to significantly increase the cell survival in primary kidney cell cultures exposed to oxidative stress, possibly involving interaction with the endogenous scavenger system, it failed to influence the viability of normal or cancerous hepatocytes.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20676802     DOI: 10.1007/s12031-010-9428-8

Source DB:  PubMed          Journal:  J Mol Neurosci        ISSN: 0895-8696            Impact factor:   3.444


  51 in total

1.  Tissue specific expression of different human receptor types for pituitary adenylate cyclase activating polypeptide and vasoactive intestinal polypeptide: implications for their role in human physiology.

Authors:  Y Wei; S Mojsov
Journal:  J Neuroendocrinol       Date:  1996-11       Impact factor: 3.627

2.  Endogenous PACAP acts as a stress response peptide to protect cerebellar neurons from ethanol or oxidative insult.

Authors:  David Vaudry; Carol Hamelink; Ruslan Damadzic; Robert L Eskay; Bruno Gonzalez; Lee E Eiden
Journal:  Peptides       Date:  2005-07-11       Impact factor: 3.750

3.  Molecular cloning and functional characterization of a human liver vasoactive intestinal peptide receptor.

Authors:  A W Gagnon; N Aiyar; N A Elshourbagy
Journal:  Cell Signal       Date:  1994-03       Impact factor: 4.315

4.  Characterization of vasoactive intestinal peptide receptors in human liver.

Authors:  N Rodríguez-Henche; M S Rodríguez-Pena; L G Guijarro; J C Prieto
Journal:  Biochim Biophys Acta       Date:  1994-03-31

5.  Effects of PACAP on in vitro and in vivo neuronal cell death, platelet aggregation, and production of reactive oxygen radicals.

Authors:  Dóra Reglodi; Zsolt Fábián; Andrea Tamás; Andrea Lubics; József Szeberényi; Tamás Alexy; Kálmán Tóth; Zsolt Márton; Balázs Borsiczky; Erzsébet Rõth; Luca Szalontay; István Lengvári
Journal:  Regul Pept       Date:  2004-12-15

6.  Regulatory peptide receptors in human hepatocellular carcinomas.

Authors:  J C Reubi; A Zimmermann; S Jonas; B Waser; P Neuhaus; U Läderach; B Wiedenmann
Journal:  Gut       Date:  1999-11       Impact factor: 23.059

7.  VPAC1 expression is regulated by FXR agonists in the human gallbladder epithelium.

Authors:  Nicolas Chignard; Martine Mergey; Véronique Barbu; Laetitia Finzi; Emmanuel Tiret; Annick Paul; Chantal Housset
Journal:  Hepatology       Date:  2005-09       Impact factor: 17.425

8.  Effects of pituitary adenylate cyclase activating polypeptide on the survival and signal transduction pathways in human choriocarcinoma cells.

Authors:  A Boronkai; R Brubel; B Racz; A Tamas; P Kiss; G Horvath; A Lubics; A Szigeti; Sz Bellyei; G Toth; A Lakatos; D Reglodi
Journal:  Ann N Y Acad Sci       Date:  2009-04       Impact factor: 5.691

9.  Pituitary adenylate cyclase-activating polypeptide induces expression of corticosteroid-binding globulin in cultured fetal hepatocytes: synergy with tri-iodothyronine.

Authors:  E el Fahime; B Lutz-Bucher; J M Felix; B Koch
Journal:  Biochem J       Date:  1996-04-15       Impact factor: 3.857

10.  Pituitary adenylate cyclase-activating polypeptide ameliorates cisplatin-induced acute kidney injury.

Authors:  Min Li; Saravanan Balamuthusamy; Altaf M Khan; Jerome L Maderdrut; Eric E Simon; Vecihi Batuman
Journal:  Peptides       Date:  2009-12-23       Impact factor: 3.750

View more
  17 in total

1.  Neuropeptide PACAP in mouse liver ischemia and reperfusion injury: immunomodulation by the cAMP-PKA pathway.

Authors:  Haofeng Ji; Yu Zhang; Xiu-da Shen; Feng Gao; Cynthia Y Huang; Catalina Abad; Ronald W Busuttil; James A Waschek; Jerzy W Kupiec-Weglinski
Journal:  Hepatology       Date:  2013-01-18       Impact factor: 17.425

2.  Protective Effect of PACAP on Ischemia/Reperfusion-Induced Kidney Injury of Male and Female Rats: Gender Differences.

Authors:  Eszter Laszlo; Tamas Juhasz; Adam Varga; Bernadett Czibere; Krisztina Kovacs; Peter Degrell; Gabriella Horvath; Gabor Jancso; Peter Szakaly; Andrea Tamas; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2018-11-16       Impact factor: 3.444

3.  Pituitary adenylate cyclase-activating polypeptide (PACAP) signalling enhances osteogenesis in UMR-106 cell line.

Authors:  Tamás Juhász; Csaba Matta; Éva Katona; Csilla Somogyi; Roland Takács; Tibor Hajdú; Solveig Lind Helgadottir; János Fodor; László Csernoch; Gábor Tóth; Éva Bakó; Dóra Reglődi; Andrea Tamás; Róza Zákány
Journal:  J Mol Neurosci       Date:  2014-08-12       Impact factor: 3.444

4.  Pituitary Adenylate Cyclase-activating Polypeptides Prevent Hepatocyte Damage by Promoting Yes-associated Protein in Liver Ischemia-Reperfusion Injury.

Authors:  Yuan Liu; Tianfei Lu; Cheng Zhang; Zhengze Xue; Jin Xu; Ronald W Busuttil; Qiang Xia; Ning Xu; Jerzy W Kupiec-Weglinski; Haofeng Ji
Journal:  Transplantation       Date:  2019-08       Impact factor: 4.939

5.  Age-related decline of autocrine pituitary adenylate cyclase-activating polypeptide impairs angiogenic capacity of rat cerebromicrovascular endothelial cells.

Authors:  Eszter Banki; Danuta Sosnowska; Zsuzsanna Tucsek; Tripti Gautam; Peter Toth; Stefano Tarantini; Andrea Tamas; Zsuzsanna Helyes; Dora Reglodi; William E Sonntag; Anna Csiszar; Zoltan Ungvari
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2014-08-18       Impact factor: 6.053

6.  Investigation of the possible functions of PACAP in human trophoblast cells.

Authors:  G Horvath; D Reglodi; R Brubel; M Halasz; A Barakonyi; A Tamas; E Fabian; B Opper; G Toth; M Cohen; L Szereday
Journal:  J Mol Neurosci       Date:  2014-05-30       Impact factor: 3.444

7.  Examination of PACAP-Like Immunoreactivity in Urogenital Tumor Samples.

Authors:  Andrea Tamas; Andras Javorhazy; Dora Reglodi; Donat Peter Sarlos; Daniel Banyai; David Semjen; Jozsef Nemeth; Beata Lelesz; Daniel Balazs Fulop; Zalan Szanto
Journal:  J Mol Neurosci       Date:  2015-10-10       Impact factor: 3.444

8.  Molecular mechanisms underlying the Nephroprotective effects of PACAP in diabetes.

Authors:  Eszter Banki; Krisztina Kovacs; Daniel Nagy; Tamas Juhasz; Peter Degrell; Katalin Csanaky; Peter Kiss; Gabor Jancso; Gabor Toth; Andrea Tamas; Dora Reglodi
Journal:  J Mol Neurosci       Date:  2014-02-19       Impact factor: 3.444

Review 9.  Microglia-Induced Maladaptive Plasticity Can Be Modulated by Neuropeptides In Vivo.

Authors:  Stefano Morara; Anna Maria Colangelo; Luciano Provini
Journal:  Neural Plast       Date:  2015-07-26       Impact factor: 3.599

10.  Pituitary adenylate cyclase activating polypeptide (PACAP) signalling exerts chondrogenesis promoting and protecting effects: implication of calcineurin as a downstream target.

Authors:  Tamás Juhász; Csaba Matta; Éva Katona; Csilla Somogyi; Roland Takács; Pál Gergely; László Csernoch; Gyorgy Panyi; Gábor Tóth; Dóra Reglődi; Andrea Tamás; Róza Zákány
Journal:  PLoS One       Date:  2014-03-18       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.